Targeting Syk as a treatment for allergic and autoimmune disorders. - Wikidata - wikimedia - TriplyDB

Targeting Syk as a treatment for allergic and autoimmune disorders.

Targeting Syk as a treatment for allergic and autoimmune disorders.

http://www.wikidata.org/entity/Q35814437

about

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Molecular mechanism of the Syk activation switch Functional roles of Syk in macrophage-mediated inflammatory responses Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation Regulation of Fc∈RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain.Tyrosine kinases in inflammatory dermatologic disease.Deletion of Syk in neutrophils prevents immune complex arthritis Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.Functional gastrointestinal disorders and mast cells: implications for therapy.Microsomal prostaglandin E synthase-1, ephrins, and ephrin kinases as suspected therapeutic targets in arthritis: exposed by "criminal profiling".Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation.Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness The tyrosine kinase network regulating mast cell activation.Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.Therapeutic prospect of Syk inhibitors.Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.The discovery of novel experimental therapies for inflammatory arthritis.Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.Targeting kinases for the treatment of inflammatory diseases.B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies.Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.Arsenic inhibits mast cell degranulation via suppression of early tyrosine phosphorylation events.Inhibitory effect of the branches of Hovenia dulcis Thunb. and its constituent pinosylvin on the activities of IgE-mediated mast cells and passive cutaneous anaphylaxis in mice.The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.Homoisoflavanone prevents mast cell activation and allergic responses by inhibition of Syk signaling pathway.Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Development of a HTRF kinase assay for determination of Syk activity.Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey.Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress.

P2860

Q21195261-24D6718A-203D-48B5-A24E-103D05E396B3 Q24316139-62D87BB3-6638-475D-B32B-C30794EADEE2 Q26851134-9712AA12-07BC-42CA-AF48-4669C79B09F7 Q28078946-92B2256F-FF67-40DD-AA7F-9D5F4C568721 Q28292048-33664B32-D7D0-40AA-BD0C-B493FB4642C6 Q28552367-CD7672EC-1FEA-4840-A302-9602865E1EB3 Q33947182-4B5F1021-7201-493C-B586-274D853A3230 Q34166503-8EF77A13-3010-4FAD-9081-1F21F3B75550 Q35269028-05A80862-8C6B-4AAF-A7A3-5EADF4949D39 Q36268287-D2866F44-A361-4273-8530-E687498A597D Q36349789-A6C3ED5A-415E-4779-889E-0FE6C7FCB824 Q36541314-4B016A81-7FED-4852-BD6A-07157079A938 Q36987997-E8DE0EDB-E577-45A0-ADD1-93FF842D4C3E Q37101076-5B969048-C724-4C88-933E-7384D567E6C0 Q37144550-305B62C8-9DD7-439F-9E6E-7160F07384FE Q37158872-6FCAFD26-8427-4A44-B512-A8825CE1F70D Q37196300-D16812E1-AEFE-4515-BB5B-62B93418D407 Q37577893-39E82DE8-6295-4D0D-ACB9-4AF667F381AA Q37596764-A5D302FE-5851-453D-AF3F-4578A967DBCF Q37719255-41DB8F18-7474-43A1-94DA-E1CC95271BD6 Q37826463-164A3EA3-2BEE-4D8F-9C00-CB1C44DDCEC0 Q38028572-D6710DAE-B57A-4952-9CFB-0C7175CFA2B8 Q38124120-C5A9D389-4754-4902-B139-008929CE22FD Q38169198-C35502FC-EE0D-4CD9-AE4D-6DAB1AB1AC50 Q38181610-443F93FE-F8C9-4FF0-9F96-594F73C1053E Q38189848-98AA1577-599F-458C-8CC6-72B092B4C065 Q38655324-D1F29CA0-8AEB-404C-944D-FE8D38DB19B4 Q38782943-801C5997-F274-4675-B30B-C5271DED6DC2 Q38895669-F467D983-D012-447F-942E-BDE451A2ACAF Q38925714-B2A362CC-A37A-4274-B9F0-EF8C0B9512DB Q39032424-DB510F79-6E19-42C0-9BB1-77DF2913A625 Q40330626-E5740CF2-48AD-4CCD-9D87-184571ADBAE2 Q40699579-1F5108EB-9CD2-4CBF-B42F-B2A65750D9E5 Q40782419-493E2EF1-4A4A-4396-BB23-79147EEA5D92 Q41773428-58D6AA5C-6671-466C-8216-6C16D88403EE Q42273265-FAA06F2F-D018-45BF-BA15-5C4BCE70D37F Q43087577-5530752C-0B30-4089-8A27-247DFC40BEBD Q43203308-E0F2EFAC-AA7B-4179-8677-D92B883AA0FC Q43219262-EAAB2152-93A0-41B6-BCAB-381FDC75AE8D Q43888734-4E833A0D-9882-47CF-ABE1-69425DCE53AA

P2860

Targeting Syk as a treatment for allergic and autoimmune disorders.

http://www.wikidata.org/entity/Q35814437

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Targeting Syk as a treatment for allergic and autoimmune disorders.

@ast

Targeting Syk as a treatment for allergic and autoimmune disorders.

@en

type

label

Targeting Syk as a treatment for allergic and autoimmune disorders.

@ast

Targeting Syk as a treatment for allergic and autoimmune disorders.

@en

prefLabel

Targeting Syk as a treatment for allergic and autoimmune disorders.

@ast

Targeting Syk as a treatment for allergic and autoimmune disorders.

@en

P1433

Q35814437-084400AB-E971-409C-A4D1-428910F26143

P1476

Q35814437-D3E24DBA-884D-4845-9D5D-0EE81F26B487

P2093

Q35814437-5FECE127-2984-470F-B4FE-4D902C4BA54D

Q35814437-69112570-F325-4114-8106-CC6FDE53CEB9

Q35814437-929E2AE1-ACBA-4A45-A305-6FF1BA40656B

Q35814437-FEB614D3-AFD1-4D77-A922-41EFA1636B0A

P2860

Q35814437-000B6C08-8BE9-4938-B596-F2FF63DCFC75

Q35814437-02153799-0CAE-4313-8162-95925FEA1F3B

Q35814437-036A9494-F004-4E40-AD65-687FFD2B8A01

Q35814437-05881481-64EA-4B52-9125-D6EDE8BD11E4

Q35814437-09299E92-3ED1-409E-AA84-5992494A10F2

Q35814437-0941513D-46CC-4749-91AC-ACF1B1F7B99A

Q35814437-0A0C989A-F463-47A2-AEFB-896378009800

Q35814437-0CCAE02E-1097-403A-B4C0-F792163FC432

Q35814437-0D592A5C-5B98-4B64-BA9C-33BE8CB07308

Q35814437-0ECFB021-1076-4E8E-8F83-E7B013C6D960

P304

Q35814437-90E06565-91BF-4E70-AD76-B95ED1662A5A

P31

Q35814437-02326EB3-01F1-49F2-8EA9-C996C9A4E61E

P356

Q35814437-593099FB-EF9A-4D99-8B2D-3571A7B5D64A

P407

Q35814437-DF0A0C86-6CF7-42C1-A9A5-BF9EF53B3E8A

P433

Q35814437-5EF57649-FF76-440B-965C-11751E672CEC

P478

Q35814437-46676131-2AA4-4A9C-A80D-37323E63ED47

P577

Q35814437-D750CC60-2923-4928-A285-890674522655

P698

Q35814437-1C525005-6157-4D05-ADF3-2264A4E2975F

P356

13543784.13.7.743

P1433

Expert Opinion on Investigational Drugs

P1476

Targeting Syk as a treatment for allergic and autoimmune disorders.

@en

P2093

Brian R Wong

http://www.w3.org/2001/XMLSchema#string

Donald G Payan

http://www.w3.org/2001/XMLSchema#string

Elliott B Grossbard

http://www.w3.org/2001/XMLSchema#string

Esteban S Masuda

http://www.w3.org/2001/XMLSchema#string

P2860

The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells

Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton

Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation

Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells

BLNK: a central linker protein in B cell activation

Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide

Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

P304

743-762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.13.7.743

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15212616

http://www.w3.org/2001/XMLSchema#string